If You Invested in Amedisys Inc (AMED)

Amedisys, Inc. (NASDAQ: AMED) is a healthcare at home company that focuses on delivering personalized care in the home setting. The company operates in the home health care services industry within the broader health care and social assistance sector. According to its public disclosures, Amedisys provides home health, hospice and high acuity care services designed to support patients across a range of needs, from recovery and rehabilitation after an operation or injury to the management of chronic disease and end-of-life care.

Founded in 1982 and headquartered in Baton Rouge, Louisiana, with an executive office in Nashville, Tennessee, Amedisys has developed a nationwide footprint of care centers. Company disclosures state that Amedisys operates hundreds of care centers across multiple U.S. states and the District of Columbia, employing approximately 18,000–19,000 people over recent reporting periods. These teams deliver care to hundreds of thousands of patients each year in their homes, with millions of visits performed annually.

Business focus and services

Amedisys describes itself as a healthcare at home company delivering three primary categories of services: home health, hospice and high acuity care in the home. Its home-based recovery and rehabilitation services are aimed at patients following operations or injuries. The company also provides care focused on empowering patients to manage chronic diseases in their own homes. For patients at the end of life, Amedisys offers hospice care. In addition, the company reports that it supports in-patient hospital, palliative and skilled nursing facility ("SNF") level care delivered in patients’ homes.

Amedisys notes that thousands of hospitals and more than one hundred thousand physicians nationwide have selected the company as a partner in post-acute care. This reflects its role in coordinating with hospitals, physicians and other providers to deliver home-based services after an acute care episode or as part of longer-term care plans.

Scale and network

In its earnings and corporate information releases, Amedisys reports operating more than 500 care centers in dozens of states and the District of Columbia. Across these locations, the company reports serving on the order of hundreds of thousands of patients annually, with visit volumes in the multi-million range. These figures underscore the company’s role as a large provider of home-based clinical services in the United States.

The company also reports that thousands of hospitals and well over one hundred thousand physicians have chosen Amedisys as a post-acute care partner. This network of referral relationships supports its home health, hospice and high acuity care offerings.

Clinical programs and care settings

Amedisys’ disclosures describe a range of care settings that it supports in the home. These include hospital-level care delivered at home, palliative care, and care that can substitute for a skilled nursing facility stay, all provided in the patient’s residence. The company also emphasizes home-based recovery and rehabilitation services following surgery or injury, chronic disease-focused care that aims to help patients manage ongoing conditions, and hospice services for patients at the end of life.

Through its subsidiary Contessa Health, which Amedisys identifies as an Amedisys company, the organization reports delivering comprehensive care at home, including Recovery Care at Home in lieu of a hospital admission, Rehabilitation Care at Home in lieu of a skilled nursing facility admission, and Palliative Care at Home. Contessa partners with health systems and health plans and uses a proprietary technology platform to support these models.

Quality and patient experience

Amedisys has highlighted recognition related to patient and caregiver satisfaction. In one of its news releases, the company reports that dozens of its home health and hospice care centers received SHPBest™ Patient Satisfaction Awards from Strategic Healthcare Programs (SHP) based on HHCAHPS and CAHPS Hospice survey results. These awards are based on ranking overall satisfaction scores among thousands of home health and hospice providers, and Amedisys notes that some of its care centers have been recognized repeatedly over multiple years of the SHPBest program.

The company’s statements emphasize a focus on delivering what it describes as the highest quality of care to patients’ doorsteps, and on patient, family and caregiver satisfaction as a priority in its home health and hospice operations.

Technology and clinical capabilities

Amedisys has disclosed initiatives that incorporate diagnostic and care-delivery technologies into its home-based services. In collaboration with Patient Choice Laboratories, Amedisys reports offering advanced molecular testing to its care centers nationwide for the identification of pathogens in urine, respiratory and wound infections. The company states that this molecular testing is intended to provide rapid and precise results to support timely and targeted treatment decisions in the home setting.

Through Contessa, Amedisys also references the use of a proprietary technology platform to support comprehensive care at home programs. These programs are designed to combine elements of inpatient hospital or rehabilitation stays with home-based care, in coordination with health systems and health plans.

Corporate structure and ownership

Amedisys has disclosed that it was a publicly held company listed on the Nasdaq Stock Market under the symbol AMED. On August 14, 2025, according to a Current Report on Form 8-K, Amedisys completed a merger with Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group Incorporated, under an Agreement and Plan of Merger originally dated June 26, 2023 and modified by a waiver dated December 26, 2024. At the effective time of the merger, Merger Sub merged with and into Amedisys, with Amedisys surviving as a wholly owned subsidiary of UnitedHealth Group.

In connection with this transaction, Amedisys reported that each share of Amedisys common stock (other than specified excluded shares) was converted into the right to receive a cash amount per share as described in the Form 8-K. Following the merger, Amedisys became an indirect wholly owned subsidiary of UnitedHealth Group, and Amedisys stockholders ceased to have rights as stockholders of Amedisys other than the right to receive the merger consideration described in the merger agreement.

Delisting and deregistration

On August 14, 2025, Amedisys filed a Form 8-K stating that it had notified The Nasdaq Stock Market LLC of the closing of the merger and requested suspension of trading in Amedisys common stock, withdrawal of the listing from Nasdaq and the filing of a Form 25 to delist the common stock and deregister it under Section 12(b) of the Securities Exchange Act of 1934. A Form 25 filed by Nasdaq on August 14, 2025, identifies Amedisys, Inc. as the issuer and the Nasdaq Stock Market LLC as the exchange, and relates to the removal of Amedisys common stock from listing and/or registration under Section 12(b) of the Exchange Act.

Subsequently, on August 25, 2025, Amedisys filed a Form 15 certifying the termination of registration of its common stock under Section 12(g) of the Exchange Act and the suspension of its duty to file reports under Sections 13 and 15(d) of the Exchange Act. The Form 15 explains that, as of August 14, 2025, Merger Sub had merged with and into Amedisys, with Amedisys surviving as a wholly owned subsidiary of UnitedHealth Group, and indicates an approximate number of holders of record of one as of the certification date.

Regulatory and legal context

Amedisys’ public filings describe regulatory and legal processes related to the merger. In an August 7, 2025 Form 8-K, the company reported that the U.S. Department of Justice and several state attorneys general filed a proposed final judgment with a federal district court to resolve opposition to the merger, subject to judicial approval under the Antitrust Procedures and Penalties Act. The company’s earnings and other releases also discuss risks related to Medicare and other payment levels, government regulation, staffing, competition in the healthcare industry, and other factors that could affect its operations.

Historical role in home health care

Before becoming a wholly owned subsidiary of UnitedHealth Group, Amedisys operated as a publicly traded healthcare at home company focusing on home health, hospice and high acuity care services. Over multiple years of public reporting, the company consistently described its mission as delivering personalized care in the home, coordinating with hospitals and physicians as a post-acute care partner, and serving large numbers of patients across many states through its network of care centers.